A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis

This study has been completed.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002169
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: May 1999
  Purpose

The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.


Condition Intervention Phase
Cytomegalovirus Retinitis
HIV Infections
Drug: Nelfinavir mesylate
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection

Resource links provided by NLM:


Further study details as provided by NIH AIDS Clinical Trials Information Service:

  Eligibility

Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Patients must have:

  • HIV infection.
  • Newly diagnosed or first progression of CMV retinitis.

Exclusion Criteria

Prior Medication:

Excluded:

Prior therapy (or less than 2 weeks) with protease inhibitor other than saquinavir.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002169

Locations
United States, California
Univ of Southern California / LA County USC Med Cntr
Los Angeles, California, United States, 90033
Univ of California / UCI Med Ctr
Orange, California, United States, 92868
Univ of California / San Diego Treatment Ctr
San Diego, California, United States, 92103
Harbor UCLA Med Ctr
Torrance, California, United States, 90502
United States, District of Columbia
George Washington Univ
Washington, District of Columbia, United States, 20037
United States, Illinois
Northwestern Univ / SOCA
Chicago, Illinois, United States, 60611
United States, Texas
Univ of Texas Med Branch
Galveston, Texas, United States, 77555
Baylor Univ
Houston, Texas, United States, 77009
Sponsors and Collaborators
Agouron Pharmaceuticals
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00002169     History of Changes
Other Study ID Numbers: 259A, Study 517, AG1343-517
Study First Received: November 2, 1999
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:
AIDS-Related Opportunistic Infections
Placebos
Antiviral Agents
Cytomegalovirus Retinitis
Treatment Outcome
Nelfinavir

Additional relevant MeSH terms:
Infection
Communicable Diseases
Retinitis
HIV Infections
Acquired Immunodeficiency Syndrome
Cytomegalovirus Retinitis
Retinal Diseases
Eye Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Cytomegalovirus Infections
Herpesviridae Infections
DNA Virus Infections
Eye Infections, Viral
Eye Infections
Nelfinavir
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents

ClinicalTrials.gov processed this record on September 16, 2014